Hinova Pharmaceuticals Inc
688302
Company Profile
Business description
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
Contact
No. 5 Keyuan South Road
No. 2 and 3, 4th Floor, Building 1, Rongyao Building
High-tech Zone, Sichuan Province
Chengdu610041
CHNT: +86 2885058465
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
174
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.20 | 45.20 | -0.50% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 25,888.82 | 274.42 | -1.05% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,058.08 | 527.78 | -0.89% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,776.10 | 43.40 | -0.49% |
| SSE Composite Index | 4,086.79 | 19.47 | -0.47% |